Zolbetuximab, also known by the alias claudixmab, is a targeted therapeutic drug against CLDN18.2, and it has shown significant potential in the treatment of gastric cancer. With the arrival of 2025, its latest price, adverse reactions, and therapeutic efficacy have become the focus of attention for patients. Then, what is the latest price of zolbetuximab in 2025?

Latest Price of Zolbetuximab in 2025

Zolbetuximab has been launched in China but not included in the national medical insurance catalog, so its price has always been a key concern for patients and their families.

Price Trends of Original Research Drugs

Currently, the original research drug of zolbetuximab is produced by Astellas Pharma Inc. of Japan, and its price varies across different countries and regions. The specification of zolbetuximab is 100mg per vial, with a price of approximately 1,482 US dollars per box. Due to factors such as R&D costs and patent protection, the price of the original research drug remains at a relatively high level.

Price Expectations for Generic Drugs

With the continuous advancement of generic drug R&D, the launch of generic drugs will increase market supply, thereby lowering drug prices. It is expected that in the next few years, the price of generic zolbetuximab will show a significant downward trend, providing patients with more cost-effective treatment options.

Adverse Reactions of Zolbetuximab

During the use of zolbetuximab, patients may experience a series of adverse reactions, which may affect their treatment experience and efficacy.

Common Adverse Reactions

Common adverse reactions of zolbetuximab include allergic reactions, nausea, vomiting, etc. Allergic reactions may manifest as symptoms such as rash, pruritus, and shortness of breath, and in severe cases, anaphylactic shock may occur. Nausea and vomiting are common gastrointestinal reactions of antineoplastic drugs, which can be alleviated by adjusting the diet, using antiemetic drugs, and other methods.

Severe Adverse Reactions and Countermeasures

In addition to common adverse reactions, zolbetuximab may also cause some severe adverse reactions, such as laryngeal edema and electrolyte disorders. For these severe reactions, patients should seek medical attention immediately and take corresponding treatment measures. Doctors may adjust the drug dosage or discontinue the drug according to the specific conditions of the patients.

Therapeutic Efficacy of Zolbetuximab

Zolbetuximab has shown significant efficacy in the treatment of unresectable advanced recurrent gastric cancer positive for Claudin18.2 (CLDN18.2). The evaluation of its therapeutic efficacy is mainly based on clinical trial data and patients' actual treatment experience.

Support from Clinical Trial Data

Clinical trial data of zolbetuximab show that this drug can significantly improve patients' survival time and quality of life. In a clinical trial involving patients with advanced gastric cancer, the combination therapy regimen of zolbetuximab and chemotherapy significantly prolonged the progression-free survival and overall survival of patients. These data provide strong support for the clinical application of zolbetuximab.

Feedback from Patients' Treatment Experience

In addition to clinical trial data, patients' actual treatment experience is also an important basis for evaluating the therapeutic efficacy of zolbetuximab. Many patients reported that after receiving zolbetuximab treatment, their symptoms were significantly relieved and their quality of life was improved.

Patients and the medical community should fully understand this information to make informed treatment decisions.